In the past 18 months there have been several important developments related to the GDPR, including the Schrems II decision, the resulting European Data Protection Board guidance on cross-border data transfers, and the issuance of revised Standard Contractual Clauses. This presentation addressed how each of these items affects researchers.
Released on: November 9, 2021
Topics: 1) The Regulation of Digital Health Tools and Software as a Medical Device, and 2) Update on the Application of the European Union’s General Data Protection Regulation to Research
October 2021: Demystifying Schrems II for the Cross-Border Transfer of Clinical Research Data
September 2021: Comments on European Data Protection Board Guidelines 04/2021 on Codes of Conduct as Tools for Transfers
October 2020: How to Fix the GDPR’s Frustration of Global Biomedical Research
April 2020: Comments to the European Commission on the Challenges that GDPR Raises for Research
March 2020: Disruptive and Avoidable: GDPR Challenges to Secondary Research Uses of Data
February 2019: Guidance Regarding Interaction Between GDPR and EU Clinical Trials Regulation Leaves Several Questions Unanswered
January 2019: Letter to the European Data Protection Board on the Board’s November 2018 Draft Guidance on the Territorial Scope of the GDPR